JP2025512121A5 - - Google Patents
Info
- Publication number
- JP2025512121A5 JP2025512121A5 JP2025503026A JP2025503026A JP2025512121A5 JP 2025512121 A5 JP2025512121 A5 JP 2025512121A5 JP 2025503026 A JP2025503026 A JP 2025503026A JP 2025503026 A JP2025503026 A JP 2025503026A JP 2025512121 A5 JP2025512121 A5 JP 2025512121A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- ang
- vegf
- sequence
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210356939.6 | 2022-04-02 | ||
| CN202210356939.6A CN116925234B (zh) | 2022-04-02 | 2022-04-02 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| PCT/CN2023/085610 WO2023186131A1 (zh) | 2022-04-02 | 2023-03-31 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512121A JP2025512121A (ja) | 2025-04-16 |
| JP2025512121A5 true JP2025512121A5 (cg-RX-API-DMAC7.html) | 2026-03-13 |
Family
ID=88199501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025503026A Pending JP2025512121A (ja) | 2022-04-02 | 2023-03-31 | 抗ＶＥＧＦ－Ａおよび抗Ａｎｇ－２二重特異性抗体をコードするＡＡＶベクター |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250223345A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4506367A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512121A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116925234B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023186131A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2117477C (en) * | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| ZA200705695B (en) * | 2004-12-21 | 2009-02-25 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| EP1962903B1 (en) * | 2005-12-15 | 2013-03-13 | MedImmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| SI3495387T1 (sl) * | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| KR20150063847A (ko) * | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-A/항 Ang2 이중 특이 항체 |
| WO2016075035A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| JP2017537896A (ja) * | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| JP6983824B2 (ja) * | 2016-07-04 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 新規抗体フォーマット |
| CN109863171B (zh) * | 2016-08-23 | 2023-08-04 | 免疫医疗有限公司 | 抗vegf-a和抗ang2抗体及其用途 |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| CN116323663A (zh) * | 2020-09-04 | 2023-06-23 | 豪夫迈·罗氏有限公司 | 与vegf-a和ang2结合的抗体及其使用方法 |
| WO2022059800A1 (en) * | 2020-09-15 | 2022-03-24 | Santen Pharmaceutical Co., Ltd. | Bispecific binding molecules against vegf and ang2 |
| CN113185613B (zh) * | 2021-04-13 | 2022-09-13 | 武汉大学 | 新型冠状病毒s蛋白及其亚单位疫苗 |
| CN115772544B (zh) * | 2021-09-06 | 2024-04-26 | 合肥星眸生物科技有限公司 | 抗vegf-a和ang-2的aav载体 |
-
2022
- 2022-04-02 CN CN202210356939.6A patent/CN116925234B/zh active Active
-
2023
- 2023-03-31 CN CN202380017956.XA patent/CN118574856A/zh active Pending
- 2023-03-31 EP EP23778495.4A patent/EP4506367A4/en active Pending
- 2023-03-31 JP JP2025503026A patent/JP2025512121A/ja active Pending
- 2023-03-31 WO PCT/CN2023/085610 patent/WO2023186131A1/zh not_active Ceased
- 2023-03-31 US US18/853,409 patent/US20250223345A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022203494B2 (en) | Adeno-Associated Virus Variant Capsids And Use For Inhibiting Angiogenesis | |
| JP6868572B2 (ja) | アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製 | |
| Vandenberghe et al. | Tailoring the AAV vector capsid for gene therapy | |
| JP2023531451A5 (cg-RX-API-DMAC7.html) | ||
| Rabinowitz et al. | Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity | |
| CN116096377B (zh) | 跨物种相容的腺相关病毒组合物及其使用方法 | |
| EP2007795B1 (en) | Aav capsid proteins | |
| JP2024514956A5 (cg-RX-API-DMAC7.html) | ||
| CN116209768A (zh) | 用于通过高变区交换工程化新杂合aav衣壳的方法 | |
| EP4004214A1 (en) | Engineered nucleic acid regulatory element and methods of uses thereof | |
| TW201704253A (zh) | 殼體 | |
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| US20260055144A1 (en) | Recombinant adeno-associated viruses and uses thereof | |
| TW202434886A (zh) | 用於偵測及評估病毒及類病毒顆粒的方法 | |
| Belova et al. | Approaches to purification and concentration of rAAV vectors for gene therapy | |
| US20250207126A1 (en) | Modified muscle-specific promoters | |
| JP2021511020A5 (cg-RX-API-DMAC7.html) | ||
| US12624367B2 (en) | AAV6 variants | |
| AU2024290842A1 (en) | Engineered aav capsid proteins | |
| WO2025128551A1 (en) | Aav-based anti-ga therapy | |
| JP2025525027A (ja) | アデノ随伴ウイルスベクターならびに転移のリスク低減、処置、および予防のためのそれらの使用方法 | |
| WO2024216244A9 (en) | Targeting aav capsids, methods of manufacturing and using same | |
| WO2023077092A1 (en) | Engineered nucleic acid regulatory elements and methods and uses thereof | |
| JP2025525035A (ja) | アデノ随伴ウイルスベクターならびに転移のリスク低減、処置、および予防のためのそれらの使用方法 | |
| CN119264217A (zh) | 具有变异衣壳蛋白的腺相关病毒及其应用 |